Biotech News

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology (KURA)Kura Oncology2026-07-03 11:30 ESTCompany update

SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board

Open original release

Related news

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports First Quarter 2026 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

View all latest news

Kura Oncology

Kura Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.

Recent company news

KURAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

KURAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

KURABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

KURAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

KURAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 10.91 USD
Market cap: 1.02B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States